Advertisement

Pharmacokinetic Modeling and the Teratologist

  • J. F. Young
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 65)

Abstract

Pharmacokinetics has proven to be an exceptional tool in pharmaceutical and pharmacologic research. Its development has enhanced the capabilities of providing optimum dosing schedules and formulations for delivery of ethical drugs by relating blood levels of a particular drug to its therapeutic efficacy. Likewise, perturbations in the pharmacokinetic parameters of a compound produced by interactions with a second chemical or with fiver or kidney insufficiency, for example, have provided a more logical basis for the study of drug-drug or drug-chemical interactions, as well as effects of disease states in clinical pharmacology.

Keywords

Central Compartment Elimination Rate Constant Peripheral Compartment Absorption Rate Constant Deep Compartment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barr WH (1969) Factors involved in the assessment of systemic or biologic availability of drug products. Drug Inf Bull 3:27Google Scholar
  2. Berlin NI, Berman M, Berk PD, Phang JM, Waldmann TA (1968) The application of multicompartmental analysis to problems of clinical medicine, Ann Intern Med 68:423PubMedGoogle Scholar
  3. Cutler DJ (1978) On the definition of the compartment concept in pharmacokinetics. J Theor Biol 73:329PubMedCrossRefGoogle Scholar
  4. Dost FH (1953) Der Blutspiegel: Kinetic der Konzentrations-aublaute in der Kreislaufflüssigkeit. G Thieme, LeipzigGoogle Scholar
  5. Dost FH (1958) Klin Wochschr 36:665CrossRefGoogle Scholar
  6. Feldman S (1974) Drug distribution, Med Clin North Am 58:917PubMedGoogle Scholar
  7. Garrett ER (1969) Basic concepts and experimental methods of pharmacokinetics. Adv Biosci 5:7Google Scholar
  8. Garrett ER (1970) Clinical significance of pharmacokinetics. In: Dengler HJ (ed) Pharmacological and clinical significance of pharmacokinetics, Symposia in medica Hoechst, F.K. Schaffauer-Verlag, Stuttgart New York pp. 5–21Google Scholar
  9. Garrett ER (1973) Classical pharmacokinetics to the frontier. J Pharmacokinet Biopharm 1:341PubMedCrossRefGoogle Scholar
  10. Garrett ER, Johnston RL, Collins EJ (1962) Kinetics of steroid effects on Ca47 dynamics in dogs with the analog computer. I. J Pharm Sci 51:1050CrossRefGoogle Scholar
  11. Garrett ER, Johnston RL, Collins EJ (1963) Kinetics of steroid effects on Ca47 dynamics in dogs with the analog computer. II. J Pharm Sci 52:668PubMedCrossRefGoogle Scholar
  12. Garrett ER, Bres J, Schnelle K, Rolf LL Jr (1974) Pharmacokinetics of saturably metabolized amobarbital. J Pharmacokinet Biopharm 2:43CrossRefGoogle Scholar
  13. Gibaldi M (1971) Pharmacokinetic aspects of drug metabolism. Ann NY Acad Sei 179:19CrossRefGoogle Scholar
  14. Gibaldi M, Feldman S (1969) Pharmacokinetic basis for the influence of route of administration on the area under the plasma concentration-time curve. J Pharm Sci 58:1477PubMedCrossRefGoogle Scholar
  15. Gibaldi M, Levy G, Weintraub H (1971) Drug distribution and pharmacologic effects. Clin Pharmacol Ther 12:734PubMedGoogle Scholar
  16. Haley TJ, Young JF (1978) A pharmacokinetic study of pentachlorophenol poisoning and the effects of forced diuresis. Clin Toxicol 12:41PubMedCrossRefGoogle Scholar
  17. Harris PA, Riegelman S (1969) Influence of the route of administration on the area under the plasma concentration-time curve. J Pharm Sci 58:71PubMedCrossRefGoogle Scholar
  18. Himmelstein KJ, Lutz RJ (1979) A review of the applications of physiologically based pharmacokinetic modeling. J Pharmacokin et Biopharm 7:127CrossRefGoogle Scholar
  19. Holson JF, Kimmel CA, Young JF (1980) The precision of pharmacokinetic parameters for predicting embryotoxicity endpoints. [Abstr] Presented at the 19th Annual Meeting of the Society of Toxicology, Washington DC, March 10, 1950Google Scholar
  20. Houston J, Levy BG (1976) Effect of route of administration on competitive drug biotransformation interaction: salicylamide ascorbic acid interaction in rat. J Pharmacol Exp Ther 198:284PubMedGoogle Scholar
  21. Hull CJ (1979) Symbols for compartmental models. Br J Anaesth 51:815CrossRefGoogle Scholar
  22. Jusko WJ (1972) Pharmacodynamic principles in chemical teratology: dose-effect relationships. J Pharmacol Exp Ther 183:469PubMedGoogle Scholar
  23. Kaplan SA, Jack ML, Cotler S, Alexander K (1973) Utilization of area under curve to elucidate the disposition of an extensively biotransformed drug. J Pharmacokinet Biopharm 1:201CrossRefGoogle Scholar
  24. Leferink JG, Maes RAA (1979) STRIPACT, an interactive curve fit programme for pharmacokinetic analyses. Arzneim Forsch 29:1894Google Scholar
  25. Levy G (1974 a) Pharmacokinetic control and clinical interpretation of steady-state blood levels of drugs. Clin Pharmacol Ther 16:130Google Scholar
  26. Levy G (1974 b) An orientation to clinical pharmacokinetics. In: Levy G (ed) Clinical pharmacokinetics -a symposium. American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Washington D. C. pp. 1–9Google Scholar
  27. Levy G (1976) Pharmacokinetic approaches to the study of drug interactions. Ann NY Acad Sci 281:24PubMedCrossRefGoogle Scholar
  28. Levy G, Gibaldi M, Jusko WJ (1969) Multi-compartment pharmacokinetic models and pharmacologic effects. J Pharm Sci 58:422PubMedCrossRefGoogle Scholar
  29. Niebergall PJ, Sugita ET, Schnaare RL (1974) Calculation of plasma level versus time profiles for variable dosing regimens. J Pharm Sci 63:100PubMedCrossRefGoogle Scholar
  30. Nogami H, Hanano M, Awazu S, Moon HH (1969) Pharmacokinetic analysis on the disappearance of ethoxybenzamide from plasma. Statistical treatment of data of two compartmental model by a digital computer. Chem Pharm Bull (Tokyo) 17:2097PubMedGoogle Scholar
  31. Nooney GC (1966) Mathematical models in medicine: a diagnosis. J Chronic Dis 19:325PubMedCrossRefGoogle Scholar
  32. Notari RE (1973) Pharmacokinetics and molecular modification: implications in drug design and evaluation. J Pharm Sci 62:865PubMedCrossRefGoogle Scholar
  33. Pedersen PV (1977) Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 5:513PubMedCrossRefGoogle Scholar
  34. Ramsey JC, Gehring PJ (1980) Application of pharmacokinetic principles in practice. Fed Proc 39:60PubMedGoogle Scholar
  35. Ritschel WA (1970) Biological half-lives of drugs. Drug Intell Clin Pharm 4:332Google Scholar
  36. Runner MN (1967) Comparative pharmacology in relation to teratogenesis. Fed Proc 26:1131PubMedGoogle Scholar
  37. Sedman AJ, Wagner JG (1974a) Quantitative pooling of Michaelis-Menten equations in models with parallel metabolite formation paths. J Pharmacokinet Biopharm 2:149PubMedCrossRefGoogle Scholar
  38. Sedman AJ, Wagner JG (1974 b) Importance of use of appropriate pharmacokinetic model to analyze in vivo enzyme constants. J Pharmacokinet Biopharm 2:161PubMedCrossRefGoogle Scholar
  39. Sedman AJ, Wagner JG (1974 c) AUTOAN manual. Publication Distribution Service, Ann Arbor, MichiganGoogle Scholar
  40. Seman AJ, Wagner JG (1976) CSTRIP, a Fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65:1006CrossRefGoogle Scholar
  41. Smyth RD, Hottendorf GH (1980) Application of pharmacokinetics and biopharmaceutics in the design of toxicological studies. Toxicol Appl Pharmacol 53:179–195PubMedCrossRefGoogle Scholar
  42. Taylor JD, Wiegand RG (1962) The analog computer and plasma drug kinetics. Clin Pharmacol Ther 3:464PubMedGoogle Scholar
  43. Tilstone WJ, Winchester JF, Reavey PC (1979) The use of pharmacokinetic principles in determining the effectiveness of removal of toxins from blood. Clin Pharmacokinet 4:23PubMedCrossRefGoogle Scholar
  44. Wagner JG (1968 a) Pharmacokinetics. 3. Half-life and volume of distribution. Drug Intell 2:126Google Scholar
  45. Wagner JG (1968 b) Pharmacokinetics. 4. Body water compartments and the distribution of drugs. Drug Intell 2:158Google Scholar
  46. Wagner JG (1971) “Biopharmaceutics and relevant pharmacokinetics.” Drug Intelligence Publications, Hamilton, IllinoisGoogle Scholar
  47. Wagner JG (1973) A modern view of pharmacokinetics. J Pharmacokinet Biopharm 1:363PubMedCrossRefGoogle Scholar
  48. Wagner JG (1976) Simple model to explain effects of plasma protein binding and tissue binding on calculated volumes of distribution, apparent elimination rate constants and clearances. Eur J Clin Pharmacol 20:425CrossRefGoogle Scholar
  49. White CG, Young JF, Holson JF (1980) Pharmacokinetic approach to analysis of the “window effect” in teratologic sensitivity [Abstr]. Presented at the 19th Annual Meeting of the Society of Toxicology, Washington, D.C., March 10, 1980Google Scholar
  50. Young JF, Haley TJ (1977) Pharmacokinetic study of a patient intoxicated with 2,4-dichlorophenoxyatic acid and 2-methoxy-3,4-dichlorobenzoic acid. Clin Toxicol 11:489PubMedCrossRefGoogle Scholar
  51. Young JF, Holson JF (1978) Utility of pharmacokinetics in designing toxicological protocols and improving interspecies extrapolation. J Environ Pathol Toxicol 2:169PubMedGoogle Scholar
  52. Young JF, Kimmel CA, Holson JF (1979) Validation of a pharmacokinetic model for rat embryonal dosimetry of salicylates during a tertogenically susceptible period. Toxicol Appl Pharmacol 48:A21Google Scholar
  53. Zettner A (1973) Principles of competitive binding assays (saturation analyses). I. Equilibrium techniques. Clin Chem 19:699PubMedGoogle Scholar
  54. Zettner A, Duly PE (1974) Principles of competitive binding assays (saturation analyses). II. Sequential saturation. Clin Chem 20:5PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • J. F. Young

There are no affiliations available

Personalised recommendations